213 related articles for article (PubMed ID: 31352718)
1. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
[TBL] [Abstract][Full Text] [Related]
2. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
3. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
Rosario PW; Mourão GF
Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
5. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
6. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
7. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
8. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
9. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
[TBL] [Abstract][Full Text] [Related]
10. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
11. Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.
Jeong GC; Song M; Park HJ; Min JJ; Bom HS; Cho SG; Park KS; Kang SR; Kim J; Song HC; Kwon SY
Nucl Med Mol Imaging; 2016 Dec; 50(4):329-336. PubMed ID: 27994688
[TBL] [Abstract][Full Text] [Related]
12. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
13. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
16. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
[TBL] [Abstract][Full Text] [Related]
17. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
Ramos da Silva F; Rosario PW; Mourão GF
Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
19. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
Tian T; Kou Y; Huang R; Liu B
Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
[TBL] [Abstract][Full Text] [Related]
20. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
